1 January 2022 in Women's Health
Objectives: The aim of this study was to describe the psychological impact of the COVID-19 pandemic and the specific impact of a universal SARS-CoV-2 testing programme on obstetric patients and healthcare workers at The Ottawa Hospital. Methods: This was a follow-up survey study of obstetric healthcare workers and then-pregnant patients who participated in a SARS-CoV-2 testing programme conducted in The Ottawa Hospital obstetrical triage units from 19 October to 17 November 2020. Surveys explored the effects of the COVID-19 pandemic and the testing programme on participants’ psychological well-being. Responses were collected from April to September 2021. Descriptive summary statistics were calculated for both groups. Results: During hospitalization for delivery, obstetric patients (n = 143) worried about giving COVID-19 to their new baby (88.11%), catching COVID-19 (83.22%), and giving COVID-19 to their partner (76.22%). Patients felt relief at being tested for COVID-19 during the universal testing programme (24.65%) and at getting their results (28.87%). Patients also believed that universal SARS-CoV-2 testing was a good way to slow COVID-19 spread (79.72%), reduce anxiety (75.52%), and increase relief (76.22%). In addition, patients felt good about participating in research that could help others (91.61%). Among obstetric healthcare workers (n = 94), job satisfaction decreased and job stress increased during the COVID-19 pandemic. The universal testing programme led to minor increases in healthcare worker job stress and burden, particularly among nurses, but the majority (85.23%) believed it was a valuable research initiative. Conclusion: The COVID-19 pandemic has had a negative psychological impact on obstetric patients and healthcare workers. Universal SARS-CoV-2 testing was generally viewed favourably and may serve as an effective strategy for estimating COVID-19 prevalence without adding undue stress onto patients and healthcare workers during the pandemic.
29 March 2022 in JMIR Research Protocols
Background: Cannabis use has increased in Canada since its legalization in 2018, including among pregnant women who may be motivated to use cannabis to reduce symptoms of nausea and vomiting. However, a growing body of research suggests that cannabis use during pregnancy may harm the developing fetus. As a result, patients increasingly seek medical advice from online sources, but these platforms may also spread anecdotal descriptions or misinformation. Given the possible disconnect between online messaging and evidence-based research about the effects of cannabis use during pregnancy, there is a potential for advice taken from social media to affect the health of mothers and their babies. Objective: This study aims to quantify the volume and tone of English language posts related to cannabis use in pregnancy from January 2012 to December 2021. Methods: Modeling published frameworks for scoping reviews, we will collect publicly available posts from Twitter that mention cannabis use during pregnancy and use the Twitter Application Programming Interface for Academic Research to extract data from tweets, including public metrics such as the number of likes, retweets, and quotes, as well as health effect mentions, sentiment, location, and users’ interests. These data will be used to quantify how cannabis use during pregnancy is discussed on Twitter and to build a qualitative profile of supportive and opposing posters. Results: The CHEO Research Ethics Board reviewed our project and granted an exemption in May 2021. As of December 2021, we have gained approval to use the Twitter Application Programming Interface for Academic Research and have developed a preliminary search strategy that returns over 3 million unique tweets posted between 2012 and 2021. Conclusions: Understanding how Twitter is being used to discuss cannabis use during pregnancy will help public health agencies and health care providers assess the messaging patients may be receiving and develop communication strategies to counter misinformation, especially in geographical regions where legalization is recent or imminent. Most importantly, we foresee that our findings will assist expecting families in making informed choices about where they choose to access advice about using cannabis during pregnancy. Trial Registration: Open Science Framework 10.17605/OSF.IO/BW8DA; www.osf.io/6fb2e International Registered Report Identifier (IRRID): PRR1-10.2196/34421
20 January 2025 in Journal of Medical Internet Research
Current literature is unclear on the safety and optimal timing of delivery for pregnant individuals with gestational diabetes mellitus, which inspired our study team to conduct a web-based survey study exploring patient and provider opinions on delivery options. However, an incident of fraudulent activity with survey responses prompted a shift in the focus of the research project. Unfortunately, despite the significant rise of web-based surveys used in medical research, there remains very limited evidence on the implications of and optimal methods to handle fraudulent web-based survey responses. Therefore, the objective of this viewpoint paper was to highlight our approach to identifying fraudulent responses in a web-based survey study, in the context of clinical perinatal research exploring patient and provider opinions on delivery options for pregnancies with gestational diabetes mellitus. Initially, we conducted cross-sectional web-based surveys across Canada with pregnant patients and perinatal health care providers. Surveys were available through Research Electronic Data Capture, and recruitment took place between March and October 2023. A change to recruitment introduced a US $5 gift card incentive to increase survey engagement. In mid-October 2023, an incident of fraudulent activity was reported, after which the surveys were deactivated. Systematic guidelines were developed by the study team in consultation with information technology services and the research ethics board to filter fraudulent from true responses. Between October 14 and 16, 2023, an influx of almost 2500 responses (393 patients and 2047 providers) was recorded in our web-based survey. Systematic filtering flagged numerous fraudulent responses. We identified fraudulent responses based on criteria including, but not limited to, identical timestamps and responses, responses with slight variations in wording and similar timestamps, and fraudulent email addresses. Therefore, the incident described in this viewpoint paper highlights the importance of preserving research integrity by using methodologically sound practices to extract true data for research findings. These fraudulent events continue to threaten the credibility of research findings and future evidence-based practices.
22 December 2022 in BMJ Open
ADAlysha L J Dingwall-Harvey
Alysha L J Dingwall-Harvey
+5
Introduction Cannabis use in pregnancy and post partum is increasing. Accessibility to cannabis has expanded due to the legalisation of cannabis in Canada. Therefore, there is a critical need to monitor the impact of cannabis on pregnancy outcomes and infant neurodevelopment. This pilot study will assess the feasibility of modern recruitment and data collection strategies adapted to the current cannabis environment and inform the design of a multicentre prospective birth cohort. Methods and analysis We will establish a pregnancy and birth cohort of 50 cannabis users and 50 non-users recruited before delivery. We will follow the participants at regular visits from recruitment to 12 weeks post partum. Participants will provide demographic and socioeconomic data, report their cannabis use patterns, and provide biological samples. Biological samples include maternal and infant urine and blood, breastmilk/chestmilk, cord blood, cord tissue, placenta and meconium. All samples will be processed and stored at −80°C until analysis by immunoassay or liquid chromatography-tandem mass spectrometry to determine the presence of cannabis metabolites. In addition, partners will be invited to provide additional socioeconomic and substance use data. Ethics and dissemination Ethics was obtained from Ottawa Health Science Network Research Ethics Board through Clinical Trials Ontario (3791). Our findings will be published in peer-reviewed journals, presented at scientific conferences and shared broadly with patients, healthcare decision-makers, and project partners online and through social media. Trial registration number NCT05309226.Cite Now
25 October 2021 in OSF Preprints
Background: Cannabis use has increased in Canada since its legalization in 2018, includingamong pregnant women who may be motivated to use cannabis to reduce symptoms ofnausea and vomiting. However, a growing body of research suggests that cannabis useduring pregnancy may harm the developing fetus. As a result, patients increasingly seekmedical advice from online sources, but these platforms may also spread anecdotaldescriptions or misinformation. Given the possible disconnect between online messaging andevidence-based research about the effects of cannabis use during pregnancy, there is apotential for advice taken from social media to cause harm.Objectives: To quantify the volume and tone of English-language posts related to cannabisuse in pregnancy from January 2012 to July 2021.Methods: Modelling published frameworks for scoping reviews, we will collect publiclyavailable posts from Twitter that mention cannabis use during pregnancy and employ theTwitter Application Programming Interface (API) for Academic Research to extract data fromtweets, including public metrics such as the number of likes, retweets and quotes, as well ashealth effect mentions, sentiment, location and users interests. These data will be used toquantify how cannabis use during pregnancy is discussed on Twitter and to build a qualitativeprofile of supportive and opposing posters.Results: The CHEO Research Ethics Board reviewed our project and granted an exemptionin May 2021. As of September 2021, we have gained approval to use the Twitter API forAcademic Research and have developed a preliminary search strategy that returns over 2million unique tweets posted between 2012 and 2020.Conclusions: Understanding how Twitter is being used to discuss cannabis use duringpregnancy will help public health agencies and healthcare providers assess the messagingpatients may be receiving and develop communication strategies to counter misinformation,especially in geographical regions where legalization is recent or imminent. Most importantly,we foresee that our findings will assist expecting families in making informed choices aboutwhere they choose to access advice about using cannabis during pregnancy.
17 September 2021 in OSF Preprints
Introduction: Cannabis use has increased in Canada since its legalization in 2018, including among pregnant women who may be motivated to use cannabis to reduce symptoms of nausea and vomiting. However, a growing body of research suggests that cannabis use during pregnancy may harm the developing fetus. Patients increasingly seek medical advice from online sources, but these platforms are often used to spread anecdotal descriptions or misinformation. Given the possible disconnect between online messaging and evidence-based research about the effects of cannabis use during pregnancy, there is a potential for advice taken from social media to cause harm. We propose a scoping review of Twitter to quantify the volume and tone of English-language posts related to cannabis use in pregnancy from January 2012 to July 2021.Methods and Analysis: Using Arksey and O’Malley’s framework for scoping reviews, we will collect publicly available posts from Twitter that mention cannabis use during pregnancy and employ the Twitter Application Programming Interface (API) for Academic Research to extract data from tweets, including public metrics such as the number of likes, retweets and quotes, as well as health effect mentions, sentiment, location and users interests. These data will be used to quantify how cannabis use during pregnancy is discussed on Twitter and to build a qualitative profile of supportive and opposing posters.Ethics and Dissemination: Research ethics approval is not required for publicly accessible Twitter data. We will disseminate this review’s findings through traditional channels, including preprint and peer-reviewed publications and presentations at academic conferences. In addition, we will share our findings through professional and institutional social media accounts and web pages associated with the research team.